PDCD1 and non-small cell lung carcinoma: The current study centered on the identification of perivascular blood biomarkers for predicting the effectiveness of anti‐programmed cell death protein 1 (anti‐PD‐1) treatment and progression‐free survival (PFS) in advanced NSCLC patients, that could be applied to help determine how to change treatment plans therapeutic regimens for optimizing clinical benefits.